This observation was also corroborated in an independent Swedish cohort of patients, where comparable overall survival was observed among grade 2 and grade 3 IDH-mutant glioma patients without known CDKN2A/B deletions (11.4 years and 10.9 years, respectively)48. This evidence concerns the gene IDH1 and central nervous system cancer.